News
DXCM
69.53
+2.78%
1.88
Weekly Report: what happened at DXCM last week (1229-0102)?
Weekly Report · 1d ago
Reassessing DexCom (DXCM): Is the Market Underestimating Its Valuation After a Year of Weaker Share Price Performance?
Simply Wall St · 1d ago
2 Healthcare Stocks for Long-Term Investors and 1 We Find Risky
Barchart · 5d ago
2 Growth Stocks to Buy For 2026 and Beyond
The Motley Fool · 12/30/2025 13:20
3 Stocks Likely to Gain From Rising HSA Contribution & Medicare Premium
NASDAQ · 12/30/2025 12:33
DexCom call volume above normal and directionally bullish
TipRanks · 12/29/2025 19:25
DexCom Issues Correction for Dexcom G6 and G6 Pro Software
Benzinga · 12/29/2025 18:49
FDA- DEXCOM ISSUES CORRECTION FOR DEXCOM G6 AND G6 PRO SOFTWARE
Reuters · 12/29/2025 18:44
Weekly Report: what happened at DXCM last week (1222-1226)?
Weekly Report · 12/29/2025 09:37
DexCom, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before December 26, 2025 to Discuss Your Rights - DXCM
PR Newswire · 12/26/2025 14:00
DexCom (DXCM): Reassessing Valuation After Class Action Lawsuits and New FDA Clearance for Smart Basal
Simply Wall St · 12/25/2025 12:32
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of DexCom, Inc.(DXCM) Shareholders
PR Newswire · 12/23/2025 14:00
DexCom Faces Class Action Lawsuit Alleging Securities Fraud
Reuters · 12/23/2025 12:44
Will FDA Smart Basal Approval and New Lawsuits Change DexCom's (DXCM) Product Quality Narrative?
Simply Wall St · 12/23/2025 08:14
1 Cash-Heavy Stock for Long-Term Investors and 2 We Avoid
Barchart · 12/23/2025 03:04
Dexcom Names Jacob Leach as Incoming Chief Executive
TipRanks · 12/22/2025 22:03
DexCom Awards New CEO Jacob Leach $1.15 Million Salary and $15 Million Equity Package
Reuters · 12/22/2025 21:35
DexCom Faces Class Action Lawsuit Over Alleged Securities Fraud
Reuters · 12/22/2025 19:45
Weekly Report: what happened at DXCM last week (1215-1219)?
Weekly Report · 12/22/2025 09:37
DexCom, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - DXCM
PR Newswire · 12/22/2025 09:00
More
Webull provides a variety of real-time DXCM stock news. You can receive the latest news about Dexcom Inc through multiple platforms. This information may help you make smarter investment decisions.
About DXCM
DexCom, Inc. is a medical device company. The Company is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6, Dexcom G7, Stelo, Dexcom Share, and Dexcom ONE. The Company enables people to take control of health through innovative biosensing technology. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes.